Paper Details

  1. Home
  2. Paper Details

Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.

Author: AbdollahiMohammad, NikfarShekoufeh, TeimouriFatemeh

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Dacarbazine and temozolomide are chemotherapies used for palliative treatment of malignant melanoma. A meta-analysis of three clinical trials showed no significant difference in efficacy between the two drugs, but temozolomide was associated with a higher risk of lymphopenia. Given its higher cost and side effect profile, dacarbazine may be a better first-line treatment option.
Paper Details　
Original Abstract of the Article :
The widespread prevalence of melanoma, one of the most malignant forms of skin cancer, is increasing rapidly. Two chemotherapeutic regimens are commonly used for the palliative treatment of malignant melanoma: intravenous administration of single-agent dacarbazine or oral administration of temozolom...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/CMR.0b013e3283649a97

データ提供：米国国立医学図書館（NLM）

Dacarbazine vs. Temozolomide: A Comparison of Two Drugs for Malignant Melanoma

Malignant melanoma is a serious form of skin cancer that can spread rapidly and become life-threatening. This study compares the efficacy and side effects of two chemotherapy drugs, dacarbazine and temozolomide, in treating malignant melanoma. The researchers conducted a meta-analysis of three clinical trials involving 1314 patients to determine which drug, if either, was more effective and safe.

A Desert of Treatment Options

The researchers found that dacarbazine and temozolomide had comparable efficacy in treating malignant melanoma, with no significant difference in complete response, stable disease, or disease control rates. However, temozolomide was associated with a significantly higher risk of lymphopenia, a decrease in the number of lymphocytes in the blood. It's like choosing between two different paths in the desert, both leading to the same destination but with different challenges along the way.

Choosing the Right Path in the Desert of Cancer Treatment

This study provides valuable insights into the treatment options for malignant melanoma, highlighting the importance of weighing the benefits and risks of each drug. It's like navigating the desert, considering the terrain and potential obstacles. The study suggests that dacarbazine may be a preferable choice for patients with malignant melanoma due to its similar efficacy but lower risk of lymphopenia compared to temozolomide.

Dr. Camel's Conclusion

This meta-analysis provides valuable insights into the effectiveness and side effects of dacarbazine and temozolomide in treating malignant melanoma. The study highlights the importance of carefully considering the risks and benefits of each drug before making treatment decisions. It also underscores the need for continued research into new and more effective therapies for this challenging form of cancer.
Date :
  1. Date Completed 2015-12-15
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

23880781

DOI: Digital Object Identifier

10.1097/CMR.0b013e3283649a97

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.